Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
TScan Therapeutics ( (TCRX) ) has provided an announcement.
On March 31, 2026, TScan Therapeutics, Inc. said Vice President of Finance and principal accounting officer Leiden Dworak had resigned, effective April 10, 2026, adding that his departure did not stem from any disagreement over the company’s operations, policies or practices. The board simultaneously appointed Chief Financial Officer and principal financial officer Jason A. Amello as principal accounting officer, also effective April 10, 2026, with no additional compensation or changes to his existing arrangements tied to the expanded role.
The move consolidates TScan’s key finance and accounting responsibilities under Amello, signaling continuity in financial oversight during the leadership transition. By emphasizing the absence of disputes and maintaining Amello’s compensation structure, the company sought to reassure investors and other stakeholders that its financial governance and strategic direction remain stable despite the change.
The most recent analyst rating on (TCRX) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on TScan Therapeutics stock, see the TCRX Stock Forecast page.
Spark’s Take on TCRX Stock
According to Spark, TipRanks’ AI Analyst, TCRX is a Neutral.
The score is held down primarily by weak financial performance: large ongoing losses and substantial cash burn create meaningful financing risk despite strong gross margins and a reasonable equity base. Technicals are supportive with improving momentum above key moving averages, while corporate updates add modest upside via upcoming catalysts and stated runway. Valuation remains constrained by negative earnings and no indicated dividend support.
To see Spark’s full report on TCRX stock, click here.
More about TScan Therapeutics
TScan Therapeutics, Inc. is a biotechnology company focused on developing therapeutics, operating within the life sciences and biopharmaceuticals sector. The company’s leadership structure includes roles overseeing finance and accounting functions, reflecting its need for robust financial governance as it advances its pipeline and corporate strategy.
Average Trading Volume: 533,996
Technical Sentiment Signal: Sell
Current Market Cap: $58.61M
For an in-depth examination of TCRX stock, go to TipRanks’ Overview page.